

FOI Request: Meeting Current and Future Demand
Our Reference Number: 1314175

1. What evidence does your CCG use to assess the eye health needs of your local population?

The local public health team provide information relating to the health needs of the local population, they source data/evidence from a variety of sources including HES data, NICE guidance, RNIB and other specialist organisation.

2. What processes are in place for assessing the current and future eye health needs of your local population?

The local Public Health team are currently undertaking an evaluation of the future eye health needs for Southend CCG patients.

Please provide copies of any meeting minutes or documents which reference the work you are doing to assess current and future demand.

Report from Public Health is not yet complete, it is expected the report will inform if there is a need for change/service re-design.

3. Is there a named lead with responsibility for eye care services in your CCG? (please tick relevant box)

No

4. Does your CCG receive regular reports on eye care performance and eye health issues (please tick relevant box)?

No

5. Does your CCG access independent feedback and advice from the following experts when making commissioning decisions about eye health services? Please tick relevant boxes:

	Yes	No
ophthalmologists	X	<input type="checkbox"/>
optometrists	X	<input type="checkbox"/>
patients with a sight condition	X	<input type="checkbox"/>
social care professionals	<input type="checkbox"/>	X
public health professionals	X	<input type="checkbox"/>

6. Could you confirm that your CCG has provided funding and resources to enable patients to access the following NICE approved treatments?

	Yes	No
Ranibizumab (Lucentis) for diabetic macular oedema in those with central retinal thickness of over 400 microns	X	<input type="checkbox"/>
Dexamethasone implant (Ozurdex) for macular oedema caused by central retinal vein occlusion or branch retinal vein occlusion where laser treatment is unsuitable	X	<input type="checkbox"/>
Ranibizumab (Lucentis) for macular oedema caused by central retinal vein occlusion or branch retinal vein occlusion where laser treatment is unsuitable	X	<input type="checkbox"/>
Aflibercept (Eylea) for wet age-related macular degeneration	<input type="checkbox"/>	X

If you have answered 'no' to any of these treatments, please provide the reason why:

The CCG intends to fund Eylea but are currently working with the local hospital to agree which patients will benefit most.